Yesterday, Dec. 3, 2015, 104 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $196.39 to $17,869,068.00.

Highlighted Stocks Traded by Insiders:

Heritage Insurance Holdings (HRTG) - FREE Research Report

Apostolou Panagiotis, who is Director at Heritage Insurance Holdings, sold 15,044 shares at $22.30 on Dec. 3, 2015. Following this transaction, the Director owned 155,048 shares meaning that the stake was reduced by 8.84% with the 15,044-share transaction.

The shares most recently traded at $22.89, up $0.59, or 2.59% since the insider transaction. Historical insider transactions for Heritage Insurance Holdings go as follows:

  • 4-Week # shares sold: 30,612
  • 12-Week # shares sold: 84,700
  • 24-Week # shares sold: 172,788

The average volume for Heritage Insurance Holdings has been 275,900 shares per day over the past 30 days. Heritage Insurance Holdings has a market cap of $691.1 million and is part of the financial sector and insurance industry. Shares are up 16.16% year-to-date as of the close of trading on Thursday.

Heritage Insurance Holdings, Inc. operates as a property and casualty insurance holding company in the state of Florida. The company has a P/E ratio of 7.4. Currently, there are 3 analysts who rate Heritage Insurance Holdings a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HRTG - FREE

TheStreet Quant Ratings rates Heritage Insurance Holdings as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Heritage Insurance Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 210,000 shares at $85.09 on Dec. 3, 2015. Following this transaction, the 10% Owner owned 128.3 million shares meaning that the stake was reduced by 0.16% with the 210,000-share transaction.

The shares most recently traded at $84.80, down $0.29, or 0.34% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 205,000
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 1.1 million
  • 24-Week # shares bought: 17,157
  • 24-Week # shares sold: 1.2 million

The average volume for Eli Lilly and has been 5.6 million shares per day over the past 30 days. Eli Lilly and has a market cap of $93.7 billion and is part of the health care sector and drugs industry. Shares are up 20.39% year-to-date as of the close of trading on Thursday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The stock currently has a dividend yield of 2.37%. The company has a P/E ratio of 38.1. Currently, there are 8 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Eli Lilly and Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cara Therapeutics (CARA) - FREE Research Report

Menzaghi Frederique Ph.D., who is VP-Research & Development at Cara Therapeutics, sold 6,000 shares at $16.21 on Dec. 3, 2015. Following this transaction, the VP-Research & Development owned 141,000 shares meaning that the stake was reduced by 4.08% with the 6,000-share transaction.

The shares most recently traded at $14.20, down $2.01, or 14.15% since the insider transaction. Historical insider transactions for Cara Therapeutics go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 6,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 12,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 40,262

The average volume for Cara Therapeutics has been 286,600 shares per day over the past 30 days. Cara Therapeutics has a market cap of $421.8 million and is part of the health care sector and drugs industry. Shares are up 46.34% year-to-date as of the close of trading on Thursday.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Currently, there are 5 analysts who rate Cara Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CARA - FREE

TheStreet Quant Ratings rates Cara Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and feeble growth in its earnings per share. Get the full Cara Therapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.